Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · KREBSBIO

KREBS BIOCHM

HealthcarePharmaceuticals & Biotechnology₹125 cr market cap
₹57.15 ▼ -3.12% today As of 19 Nov 2026
52-week low ₹39.7552-week high ₹71.28

-17.2% from the 52-week high · +48.4% above the low

Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The firm develops commercially viable biotech processes for application in medicine, agriculture and industry. The company is also engaged in chemical synthesis, fermentation and enzymatic technologies. The company manufactures various products, such as Androstenedione for use as steroid intermediate, and Lovastatin and Simvastatin for anti-cholesterol. The company also undertakes contract manufacturing for pharmaceutical and multinational companies and developing products for sale in global markets. The company has also products in the pilot or research and development stages, which include Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan and Phenylephrine. The company has two manufacturing facilities, one is located at Regadichelaka, Nellore District, and another one located at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.

The short version. Promoter holding was 72.74% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

KREBS BIOCHM trades 17.2% below its 52-week high and 48.4% above its 52-week low.

Change over period: —

1M+1.9%
3M+9.0%
6M+6.9%
1Y-12.1%

4 · The owners

Who holds it, and are they adding?

Promoter holding72.74%

Unchanged over 8 quarters.

Foreign institutions0.5%

Unchanged over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter72.7472.7472.7472.7472.7472.7472.7472.740.0
FII0.50.50.50.50.50.50.50.50.0
DII000000000
Public26.7626.7626.7626.7626.7626.7626.7626.760.0

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for KREBS BIOCHM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about KREBS BIOCHM

What is the KREBS BIOCHM share price?

KREBS BIOCHM (KREBSBIO) last closed at ₹57.15, down 3.12% on the day. Its 52-week range is ₹39.75 to ₹71.28.

What is the market cap of KREBS BIOCHM?

KREBS BIOCHM has a market capitalisation of about ₹125 crore.

How are KREBS BIOCHM's latest results?

Promoter holding was 72.74% in Sep 2026, up 0.00 points over 8 quarters.

Who owns KREBS BIOCHM?

As of Sep 2026, shareholding was: Promoter 72.74%, FII 0.5%, Public 26.76%.

How many mutual funds hold KREBS BIOCHM?

0 mutual fund schemes held KREBS BIOCHM in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 31 Jan 2019 · Rights issue 21:100

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.